What the business is, and whether it's a good one at a fair price.
Operates a pharmaceutical business with two reported segments: CDMO (Contract Development and Manufacturing Organization) at INR 1,133 cr in FY26 (+24% YoY), and Branded Generics at INR 497 cr (+51% YoY). CDMO serves 350+ domestic clients including leading Indian pharma companies, manufacturing drug products to partner specifications. Branded Generics sells branded drug formulations, with a 70% domestic / 30-35% export mix. The Jammu facility completed its first full year with ~INR 300 cr revenue and reached EBITDA breakeven in Q4, exiting at an INR 90 cr+ per quarter run rate. A new Baddi block for general oral solid/liquid capacity requires INR 150-170 cr capex over FY27-FY28, with potential INR 450-500 cr revenue at optimum levels. Materials at 61.7% of revenue are the dominant input cost. Exports contributed 31% of total revenue; UK-MHRA approval for the Baddi cephalosporin facility and PIC/S certification for Jammu blocks open access to regulated international markets.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from INNOVA CAPTAB LIMITED's filed financials and exchange disclosures
INNOVA CAPTAB LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol INNOVACAP.
Yes. Over the trailing twelve months INNOVA CAPTAB LIMITED reported a net profit of ₹154 Cr on revenue of ₹1,749 Cr.
Yes. The dividend yield is 0.17% at the current price. It paid out 8% of its profit as dividend in FY26.
No. Debt stands at 0.32× equity, and it carries net debt of ₹340 Cr. That is lower than 30% of its 171 Pharmaceuticals peers.
On trailing P/E, INNOVA CAPTAB LIMITED ranks 118 of 169 in Pharmaceuticals — cheaper than 30% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session INNOVA CAPTAB LIMITED moves 1.06% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by INNOVA CAPTAB LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
